Petros Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-955.6K | $-987.0K | $-336.5K | $-922.7K | $5.4M | $-2.3M | $-9.3M | $-2.2M |
| Depreciation & Amortization | — | — | — | — | — | — | $656.1K | $739.4K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | $685.3K | $700.0K |
| Stock-Based Compensation | $117.9K | $120.3K | — | — | $74.3K | $80.0K | — | — |
| Net Cash from Operating Activities | $-863.9K | $-784.3K | $-933.5K | $-1.1M | $-3.0M | $-1.7M | $965.4K | $-771.2K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | — | $0 | $-117.3K | $-428.2K | $8.7M | $-1.1M | $-2.8M |
| Net Change in Cash | — | — | — | — | — | — | $-184.7K | $-3.6M |
| Free Cash Flow | — | — | — | — | — | — | — | — |